Effect of 5-Aza-2′-deoxycytidine on the P16 tumor suppressor gene in hepatocellular carcinoma cell line HepG2

World Journal of Gastroenterology

Volumn 7, Issue 1, 2001, Pages 131-135

  Liu, L H ^a   Xiao, W H ^a   Liu, W W ^a  

^a 304TH HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; MESSENGER RNA; PROTEIN P16;

ARTICLE; CELL LINE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR DYNAMICS; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0035110060     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v7.i1.131     Document Type: Article

References (54)

1. Epidemiological characteristics and risk factors of hepatocellular carcinoma
2. Clinical research of hepatocellular carcinoma in the 21st century
3. Effect of hepatitis C virus infection on expression of several cancer-associated gene products in hepatocellular carcinoma
4. 3 protein on P53 protein expression in hepatocarcinogenesis
5. Analysis of point mutation in site 1896 of HBV precore and its detection in the tissues and serum of HCC patients
6. Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma
7. Molecular mechanism of hepatocarcinogenesis
8. WAF1 expression and hepatic apoptosis
9. Potential roles of tumor suppressor genes and microsatellite instability in hepatocellular carcinogenesis in southern African blacks
10. Characterization of six tumor suppressor genes and microsatellite instability in hepatocellular carcinoma in southern African blacks
11. INK4 (MTSI) gene occur in a subset of patients with hepatocellular carcinoma
12. Polymorphism of p16INK4a gene and rare mutation of p15INK4b gene exon2 in primary hepatocarcinoma
13. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain
14. p53 mutations in human hepatocellular carcinomas
15. Mutation of p53 tumor suppressor gene in hepatocellular carcinoma
16. Immunohistochemical study on p53, H-rasp21, c-erbB-2 protein and PCNA expression in HCC tissues of Han and minority ethnic patients
17. Overexpression and mutations of tumor suppressor gene p53 in hepatocellular carcinoma
18. Codon 249 mutations of p53 gene in development of hepatocellular carcinoma
19. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas
20. Correlation between S-adenosyl-L-methionine content and production of c-myc, c-Ha-ras and c-Ki-ras mRNA transcripts in the early stages of rat liver carcinogenesis
21. 1 in human cancers
22. Methylation status of p16 gene in colorectal carcinoma and normal colonic mucosa
23. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing
24. Silencing of p16/CDKN2 expression in human gliomas by methylovtion and chromatin condensation
25. INK4 protein induction by 5-aza-2′-deoxycytidine
26. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
27. 5-Aza-2′-deoxycytidine and 5-Aza-cytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present, and future trends
28. DNA methylation and development
29. Cellular differentiation, cytidine analogs and DNA methylation
30. Altering gene expression with 5-azacytidine
31. Inhibition of DNA methylation by 5-Aza-2′-deoxycytidine suppresses the growth of human tumor cell lines
32. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/ cdk4
33. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
34. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13 - p22
35. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation
36. Inhibition of Ras-induced proliferation and cellular transformation by p16
37. Germline p16 mutations in familial melanoma
38. P16 gene in uncultured tumors
39. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
40. Frequent somatic mutation of the MTS1/CDK4 gene in esophageal squamous cell carcinoma
41. The MTS1 gene is frequently mutated in primary human esophageal tumors
42. Mutation rate of the CDKN2 gene in malignant gliomas
43. Mutations and altered expression of p16 in human cancer
44. INK4 in Hepatocellular carcinoma
45. Increased DNA methyltransferase expression is associated with an early stage of human hepato-carcinogenesis
46. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients
47. Repression of genes by DNA methylation depends on CpG density and promoter strength evidence for involvement of a methyl-CpG binding protein
48. Dependence of transcriptional repression on CpG methylation density
49. Cell cycle-specific reactivation of an inactive X-chromosome locus by 5-azadeoxycytidine
50. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
51. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas
52. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
53. Analysis of methylation states of CpG island at locus 17p13.3 and its significance in hepatocellular carcinoma
54. Study the mechanisms of many suppresses genes inactivation